Revenue
No reported data
Immunovant, Inc. (IMVT)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Research & development | $456.7M | $360.9M | $212.9M | $160.3M | $101.8M | $68.6M | $47.9M | $25.7M |
| Operating expenses | $532.9M | $438.2M | $282.7M | $218.3M | $156.0M | $108.1M | $66.1M | $28.4M |
| Net income | −$505.6M | −$413.8M | −$259.3M | −$211.0M | −$156.7M | −$107.4M | −$66.4M | −$28.6M |
| Basic EPSper diluted share | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | -$1.54 | -$1.29 |
| Diluted EPSper diluted share | -$2.77 | -$2.73 | -$1.88 | -$1.71 | -$1.43 | -$1.22 | -$1.54 | -$1.29 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | Gloria MelanieChief Operating Officer | SellCommon Stock | 3.0K | $38.95 | $115.5K | 224.4K |
| Jun 26, 2026Form 4 | Gloria MelanieChief Operating Officer | SellCommon Stock | 14.7K | $38.18 | $563.1K | 227.4K |
| Jun 26, 2026Form 4 | Stout Jay SChief Technology Officer | SellCommon Stock | 6.7K | $38.94 | $261.8K | 211.7K |
| Jun 26, 2026Form 4 | Stout Jay SChief Technology Officer | SellCommon Stock | 33.3K | $38.18 | $1.27M | 218.4K |
| Jun 26, 2026Form 4 | Van Tuyl ChristopherChief Legal Officer | SellCommon Stock | 2.8K | $38.96 | $110.7K | 180.6K |